Correlation Between Aravive and Effector Therapeutics
Can any of the company-specific risk be diversified away by investing in both Aravive and Effector Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Aravive and Effector Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Aravive and Effector Therapeutics, you can compare the effects of market volatilities on Aravive and Effector Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Aravive with a short position of Effector Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Aravive and Effector Therapeutics.
Diversification Opportunities for Aravive and Effector Therapeutics
0.27 | Correlation Coefficient |
Modest diversification
The 3 months correlation between Aravive and Effector is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding Aravive and Effector Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Effector Therapeutics and Aravive is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Aravive are associated (or correlated) with Effector Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Effector Therapeutics has no effect on the direction of Aravive i.e., Aravive and Effector Therapeutics go up and down completely randomly.
Pair Corralation between Aravive and Effector Therapeutics
Given the investment horizon of 90 days Aravive is expected to under-perform the Effector Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Aravive is 2.01 times less risky than Effector Therapeutics. The stock trades about -0.83 of its potential returns per unit of risk. The Effector Therapeutics is currently generating about -0.12 of returns per unit of risk over similar time horizon. If you would invest 1,925 in Effector Therapeutics on September 12, 2024 and sell it today you would lose (1,912) from holding Effector Therapeutics or give up 99.32% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Very Weak |
| Accuracy | 1.65% |
| Values | Daily Returns |
Aravive vs. Effector Therapeutics
Performance |
| Timeline |
| Aravive |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
| Effector Therapeutics |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Aravive and Effector Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Aravive and Effector Therapeutics
The main advantage of trading using opposite Aravive and Effector Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Aravive position performs unexpectedly, Effector Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Effector Therapeutics will offset losses from the drop in Effector Therapeutics' long position.The idea behind Aravive and Effector Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.| Effector Therapeutics vs. Indaptus Therapeutics | Effector Therapeutics vs. Jasper Therapeutics | Effector Therapeutics vs. RenovoRx | Effector Therapeutics vs. Ensysce Biosciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Complementary Tools
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |